Calgary, Canada
Calgary, Canada

Time filter

Source Type

Zhang Y.,Carnegie Mellon University | Padman R.,Carnegie Mellon University | Patel N.,T. J. Mccann And Associates
Journal of Biomedical Informatics | Year: 2015

Objective: Clinical pathways translate best available evidence into practice, indicating the most widely applicable order of treatment interventions for particular treatment goals. We propose a practice-based clinical pathway development process and a data-driven methodology for extracting common clinical pathways from electronic health record (EHR) data that is patient-centered, consistent with clinical workflow, and facilitates evidence-based care. Materials and methods: Visit data of 1,576 chronic kidney disease (CKD) patients who developed acute kidney injury (AKI) from 2009 to 2013 are extracted from the EHR. We model each patient's multi-dimensional clinical records into one-dimensional sequences using novel constructs designed to capture information on each visit's purpose, procedures, medications and diagnoses. Analysis and clustering on visit sequences identify distinct types of patient subgroups. Characterizing visit sequences as Markov chains, significant transitions are extracted and visualized into clinical pathways across subgroups. Results: We identified 31 patient subgroups whose extracted clinical pathways provide insights on how patients' conditions and medication prescriptions may progress over time. We identify pathways that show typical disease progression, practices that are consistent with guidelines, and sustainable improvements in patients' health conditions. Visualization of pathways depicts the likelihood and direction of disease progression under varied contexts. Discussion and conclusions: Accuracy of EHR data and diversity in patients' conditions and practice patterns are critical challenges in learning insightful practice-based clinical pathways. Learning and visualizing clinical pathways from actual practice data captured in the EHR may facilitate efficient practice review by healthcare providers and support patient engagement in shared decision making. © 2015 Elsevier Inc.


Zhang Y.,Carnegie Mellon University | Padman R.,Carnegie Mellon University | Wasserman L.,Carnegie Mellon University | Patel N.,T. J. Mccann And Associates | And 2 more authors.
IEEE Intelligent Systems | Year: 2015

In this column, the authors propose a practice-based clinical pathway development process using patient data from electronic health records. The authors aim to examine the interaction between patients' health conditions and treatment approaches, and learn the most common pathways of care to inform better patient engagement and outcomes in healthcare practices. © 2001-2011 IEEE.


News Article | December 16, 2016
Site: www.prnewswire.com

NEW YORK, Dec. 16, 2016 /PRNewswire/ -- Closing out a record-breaking year, McCann New York today announced that SHOOT Magazine has named it "Agency of the Year." SHOOT attributes the win to the agency's "penchant for breaking down barriers, bringing people together in a shared...


News Article | December 9, 2016
Site: www.theguardian.com

The world’s oldest banana brand Fyffes is to be sold to Japanese giant Sumitomo for €751m (£630m), resulting in a big payout for the McCann family, one of Ireland’s most prominent business dynasties. The deal brings together the two largest banana distributors in Asia and Europe. The McCann family, whose links with Dublin-based Fyffes date back to 1902, has agreed to sell its 11.79% stake in the Irish fruit supplier, worth nearly €87.5m. The South-Carolina based Zucker family is in line for a similar payout for its 11.83% stake. The two families and other shareholders will receive €2.23 per share in cash as well as a final dividend of two cents a share. The Irish company has recommended the deal to investors and 27% have already backed it. David McCann, executive chairman of Fyffes, said the offer was compelling. “Our employees, customers, suppliers and joint venture partners will benefit from Fyffes being part of an enlarged group with greater scale, reach and resources to broaden and accelerate delivery of Fyffes’ strategic objectives.” The takeover comes two years after Fyffes and US rival Chiquita abandoned plans for a merger that would have created the world’s largest banana company. Since then, Fyffes has been on an acquisition trail and recently added mushroom businesses to its portfolio of bananas, melons and pineapples. McCann told the Irish Times that the deal was discussed at a dinner with Sumitomo executives at the Merrion hotel in Dublin two months ago. “When discussions like this begin, you can never predict how they’re going to finish,” he said, “but this is a good transaction for our shareholders and for our people, as we expect the business as a whole to remain intact.” He said he would “stay for a period”. The business has come a long way since 1902 when McCann’s grandfather Charles set up a fruit and veg shop in Dundalk and became the first agent in Ireland for Fyffes, a then-London-based banana importer. Fyffes began in 1888 when Edward Fyffe, a tea importer, went into partnership with a fruit distributor, James Hudson, and started shipping bananas from the Canary Islands to London. The McCanns built up their business and it became known as Fruit Importers of Ireland, which floated on the Irish stock exchange in 1981 and bought Fyffes five years later. Hirohiko Imura, managing executive officer of Sumitomo, said: “We are grateful that the McCann family has provided an irrevocable commitment of support and is entrusting us to continue with them the rich Fyffes heritage. Sumitomo will provide Fyffes with experience, support and investment to continue to build on the tremendous Fyffes skills and experience and reach greater potential.”

Loading T. J. Mccann And Associates collaborators
Loading T. J. Mccann And Associates collaborators